<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Sisram Medical Ltd. ( (HK:1696) ) just unveiled an update. Sisram Medical has signed a non-binding memorandum of understanding with Sinmait Medical Technology (Beijing) Co., Ltd., an indirect wholly owned subsidiary of its controlling shareholder Shanghai Fosun Pharmaceutical, to explore establishing local manufacturing for its energy-based medical devices in China. The proposed cooperation would shorten supply chains, enhance local responsiveness, and position China as a regional production and logistics hub for the Asia-Pacific market, but any resulting arrangements could constitute notifiable and connected transactions under Hong Kong listing rules and remain subject to definitive agreements and further regulatory announcements. The most recent analyst rating on (HK:1696) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page. More about Sisram Medical Ltd. Sisram Medical Ltd., incorporated in Israel and listed in Hong Kong, operates in the medical technology sector with a focus on energy-based medical devices. The Group targets core strategic markets including the People’s Republic of China and the broader Asia-Pacific region, aiming to expand its manufacturing and logistics capabilities to better serve growing regional demand. Average Trading Volume: 566,570 Technical Sentiment Signal: Sell Current Market Cap: HK$2.03B For a thorough assessment of 1696 stock, go to TipRanks’ Stock Analysis page.</div>

600196

159506

520690

159849

513700

562600

159883

01696

516500

512290

Sisram Medical Ltd. has signed a non-binding memorandum of understanding with Sinmait Medical Technology to explore local manufacturing of its energy-based medical devices in China. This partnership aims to shorten supply chains and enhance local responsiveness, positioning China as a regional production hub. The arrangements may be subject to Hong Kong listing rules and further regulatory announcements. The current analyst rating for Sisram Medical stock (HK:1696) is a Hold with a price target of HK$4.50.

Tip Ranks

FOSUN PHARMA

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC CSI All Share Health Care Devices ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

SISRAM MED

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Sisram Medical Explores Local Manufacturing Partnership in China with Fosun Unit